Melanocortin Peptides and Blood Pressure
Melanocortin Peptide Safety
+6 mmHg
Bremelanotide (PT-141), an MC4R agonist approved for hypoactive sexual desire disorder, transiently increases systolic blood pressure by an average of 6 mmHg after each dose.
White et al., Journal of Hypertension, 2017
White et al., Journal of Hypertension, 2017
View as imageThe melanocortin system controls appetite, skin pigmentation, sexual function, and inflammation. It also raises blood pressure. This cardiovascular effect runs through every melanocortin receptor agonist that activates MC4R, from the endogenous alpha-melanocyte-stimulating hormone (alpha-MSH) to the synthetic drugs bremelanotide (PT-141) and setmelanotide. The hypertensive effect is not a side effect in the traditional sense; it is a direct pharmacological consequence of MC4R activation in the central nervous system, which increases sympathetic nerve outflow to the heart and blood vessels.[1]
White et al. (2017) used ambulatory blood pressure monitoring to characterize bremelanotide's cardiovascular profile in clinical trial participants, documenting transient systolic increases of approximately 6 mmHg and diastolic increases of approximately 3 mmHg after each dose.[1] This matters because melanocortin peptides are used or being developed for conditions (obesity, sexual dysfunction, skin disorders) where patients may already carry cardiovascular risk factors. This article covers the full evidence landscape for melanocortin-mediated blood pressure effects: the receptor pharmacology, the clinical data, the genetic evidence, and what it means for patients using these peptides. For related coverage, see our articles on Melanotan II risk profile and PT-141 adverse events.
Key Takeaways
- Bremelanotide causes transient blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking within 4 hours and resolving by 8-10 hours after dosing (White et al., Journal of Hypertension, 2017)
- The hypertensive effect is mediated by MC4R activation in the hypothalamus, which increases sympathetic nervous system outflow to the cardiovascular system (Greenfield et al., New England Journal of Medicine, 2009)
- People with loss-of-function MC4R mutations have a hypertension prevalence of 24% compared to 53% in matched controls, confirming MC4R's role in blood pressure regulation (Greenfield et al., NEJM, 2009)
- A dual MC4R/GLP-1R agonist produced sustained weight loss without the blood pressure increase seen with MC4R-selective agonists in preclinical models (Ashlaw et al., Metabolism, 2026)
- Bremelanotide is contraindicated in uncontrolled hypertension and cardiovascular disease per its FDA label
- Subthreshold melanocortin system activation sensitizes multiple anorectic pathways simultaneously, suggesting low-dose strategies may achieve appetite suppression with reduced cardiovascular side effects (Dahir et al., Journal of Clinical Investigation, 2024)
The Melanocortin System: Five Receptors, Multiple Functions
The melanocortin system consists of five G-protein-coupled receptors (MC1R through MC5R), their endogenous agonists (alpha-MSH, beta-MSH, gamma-MSH, ACTH), and the endogenous antagonists agouti-related protein (AgRP) and agouti signaling protein (ASIP). The system is central to energy homeostasis, and its cardiovascular effects are inseparable from its metabolic functions.
MC1R is expressed primarily in melanocytes and immune cells. It controls skin and hair pigmentation. Afamelanotide (Scenesse), an MC1R agonist, is approved for erythropoietic protoporphyria and does not cause meaningful blood pressure changes because MC1R does not mediate sympathetic activation.
MC3R regulates energy homeostasis through a different mechanism than MC4R. Possa-Paranhos et al. (2025) demonstrated that MC3R signaling in the medial hypothalamus regulates energy "rheostasis," the body's defense against both weight loss and weight gain. MC3R knockout mice show impaired responses to caloric challenges. MC3R's role in blood pressure is distinct from MC4R: gamma-MSH acts through MC3R to promote natriuresis (sodium excretion by the kidneys), which would tend to lower blood pressure. The net cardiovascular effect of MC3R activation is therefore more complex than MC4R's straightforward pressor response.[2]
MC4R is the primary mediator of melanocortin blood pressure effects. Expressed in the hypothalamus, brainstem, and spinal cord, MC4R activation increases sympathetic nerve activity to the heart, kidneys, and peripheral vasculature. This is the receptor responsible for the hypertensive effects of bremelanotide, setmelanotide, and endogenous alpha-MSH. Rosendo-Silva et al. (2024) documented that MC3R is also present in adipose tissue, targeted by both ghrelin and leptin, positioning it as a potential therapeutic target for metabolic disease that might avoid MC4R-mediated cardiovascular effects.[3]
MC5R is expressed in sebaceous glands and exocrine tissues. Its cardiovascular relevance is minimal, and drugs targeting MC5R selectively would not be expected to alter blood pressure through central sympathetic mechanisms.
Understanding which receptor a given melanocortin peptide activates is essential for predicting its cardiovascular profile. Endogenous alpha-MSH has highest affinity for MC4R and MC1R. ACTH activates all five receptors. Synthetic peptides can be engineered for varying receptor profiles, and the blood pressure risk tracks specifically with MC4R engagement rather than with melanocortin system activation broadly.
The key insight is that melanocortin peptides with different receptor selectivity profiles produce different cardiovascular outcomes. Non-selective agonists like Melanotan II activate all five receptors, producing skin tanning (MC1R), appetite suppression (MC4R), sexual arousal (MC4R/MC3R), and blood pressure elevation (MC4R) simultaneously. Selective agonists can, in principle, achieve specific therapeutic effects while avoiding others. For context on how the anti-inflammatory fragment KPV avoids these cardiovascular effects entirely, see our article on KPV peptide.
The MC4R-Sympathetic Nervous System Axis
The mechanism linking MC4R to blood pressure is direct and well-characterized. Alpha-MSH binding to MC4R in the paraventricular nucleus of the hypothalamus activates neurons that project to the rostral ventrolateral medulla and the intermediolateral cell column of the spinal cord. These projections increase sympathetic nerve firing to the heart (increasing heart rate and contractility), the kidneys (increasing renin release and sodium retention), and the peripheral vasculature (increasing vascular resistance).
Greenfield et al. published a landmark study in the New England Journal of Medicine (2009) examining blood pressure in humans with loss-of-function MC4R mutations. The prevalence of hypertension was 24% in MC4R-deficient subjects compared to 53% in matched controls (p=0.009). This genetic evidence confirms that MC4R is tonically active in blood pressure regulation: when the receptor is non-functional, blood pressure is lower despite the severe obesity that MC4R deficiency causes. Normally, obesity increases blood pressure through multiple mechanisms, making the low hypertension rate in MC4R-deficient obese individuals a striking finding.
In wild-type mice, intracerebroventricular alpha-MSH increased mean arterial pressure from 76 +/- 4 to 95 +/- 5 mmHg, a 25% increase. In MC4R knockout mice, the same alpha-MSH administration had no effect on blood pressure, confirming that the pressor response requires MC4R (Greenfield et al., 2009).
The sympathetic activation is not limited to blood vessel constriction. MC4R-mediated sympathetic drive affects the kidneys (promoting sodium retention through renal nerve activity), the heart (increasing contractility and rate through cardiac sympathetic nerves), and the adrenal glands (promoting catecholamine release). This multiorgan sympathetic activation explains why the blood pressure effect is consistent across different melanocortin agonists regardless of their other receptor profiles: any molecule that activates MC4R in the hypothalamus triggers the same downstream sympathetic cascade.
The relationship between MC4R and blood pressure also has implications for understanding obesity-related hypertension in the general population. In most obese individuals, increased leptin signaling activates POMC neurons in the arcuate nucleus, which release alpha-MSH that binds MC4R. This leptin-melanocortin-sympathetic axis is one of the mechanisms by which obesity raises blood pressure. Melanocortin-based obesity drugs would activate this same pathway therapeutically, creating a pharmacological tension: the drug reduces obesity (which lowers blood pressure long-term) while simultaneously activating the sympathetic pathway that obesity itself uses to raise blood pressure.
Bremelanotide (PT-141): The Clinical Blood Pressure Data
Bremelanotide is the only FDA-approved melanocortin receptor agonist used on-demand (the other, setmelanotide, is for rare genetic obesity). Its blood pressure profile is therefore the most clinically relevant dataset for understanding melanocortin cardiovascular risk.
White et al. (2017) conducted ambulatory blood pressure monitoring in bremelanotide clinical trial participants. The key findings: systolic blood pressure increased by approximately 6 mmHg and diastolic by approximately 3 mmHg after subcutaneous injection. Blood pressure peaked within 4 hours of dosing and returned to baseline by approximately 8-10 hours. Heart rate decreased by up to 5 beats per minute, a baroreceptor-mediated compensatory response to the pressure increase.[1]
The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, with a label contraindication for uncontrolled hypertension and cardiovascular disease. The labeling specifies that blood pressure should be adequately controlled before initiating treatment and that use should be limited to no more than one dose per 24 hours and no more than 8 doses per month.
Cipriani et al. (2023) evaluated bremelanotide's overall profile for HSDD, noting that despite the high frequency of adverse events (nausea 40%, flushing 20.3%, headache 11.3%), discontinuation rates were relatively low. The transient nature of the blood pressure increase, self-resolving within hours, was considered manageable for on-demand use in otherwise healthy women.[4]
Spielmans and Ellefson (2024) questioned whether bremelanotide's efficacy justified its adverse event profile, noting that the effect sizes in the Phase 3 RECONNECT trials were small by conventional standards. Their analysis raised concerns about the measurement properties of the efficacy endpoints, suggesting the clinical benefit may be more modest than initially reported.[5]
Setmelanotide: The Obesity Drug With Cardiovascular Monitoring
Setmelanotide (Imcivree), approved by the FDA in 2020 for rare genetic obesity syndromes (POMC, PCSK1, and LEPR deficiency), is a selective MC4R agonist administered daily by subcutaneous injection. Unlike bremelanotide's on-demand use, setmelanotide is a chronic therapy, which changes the cardiovascular risk calculation.
In clinical trials, setmelanotide was associated with modest blood pressure changes. The sustained daily MC4R activation means the sympathetic nervous system is chronically stimulated rather than transiently activated. The FDA label includes monitoring requirements for blood pressure and heart rate. Injection site reactions (45%), skin hyperpigmentation (44%), and nausea (26%) were the most common adverse events, with the hyperpigmentation reflecting MC1R activation by this peptide that, while MC4R-selective, retains some MC1R activity at clinical doses.
The cardiovascular data from setmelanotide trials are complicated by the fact that patients with severe genetic obesity typically have elevated cardiovascular risk at baseline. Weight loss itself lowers blood pressure, creating a dynamic where MC4R-mediated blood pressure increase competes with weight loss-mediated blood pressure decrease. In the POMC deficiency population, the substantial weight loss (average BMI reduction of approximately 25% in responders) generally dominated, producing net improvements in cardiovascular risk markers. Whether this favorable balance holds in populations with less dramatic weight loss is unknown.
Melanotan II: The Unregulated Melanocortin Agonist
Melanotan II is a non-selective melanocortin agonist used informally for skin tanning, sexual enhancement, and appetite suppression. It activates MC1R (tanning), MC4R (appetite suppression, sexual function, blood pressure increase), and MC3R. Bremelanotide is an active metabolite of Melanotan II that lacks the C-terminal amide group.
Because Melanotan II is sold as a "research chemical" rather than an approved drug, its cardiovascular risks are poorly monitored. Users self-inject without blood pressure monitoring, dose titration, or cardiovascular screening. The same MC4R-mediated sympathetic activation documented in bremelanotide clinical trials applies to Melanotan II, but at uncontrolled doses that may produce larger blood pressure excursions.
The non-selectivity of Melanotan II creates additional cardiovascular uncertainty. While MC4R activation raises blood pressure through sympathetic stimulation, MC3R activation in the kidney promotes sodium excretion, which lowers blood pressure. The net effect depends on the relative strength of these opposing forces, which varies with dose, individual receptor expression, and hydration status. In the absence of clinical monitoring, users have no way to know which effect dominates. Case reports in the dermatology and emergency medicine literature document cardiovascular events associated with Melanotan II use, though establishing causation from case reports is not possible. For a complete analysis of Melanotan II's risk profile across cardiovascular, dermatological, and other systems, see our dedicated article on Melanotan II risks.
The RECONNECT Trials: Efficacy Versus Safety
The Phase 3 RECONNECT trials that led to bremelanotide's FDA approval enrolled premenopausal women with HSDD. The trials tested 1.75 mg subcutaneous bremelanotide on demand versus placebo. The primary efficacy endpoints were changes in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score and the Female Sexual Function Index (FSFI) desire domain score.
Results showed statistically significant improvements in both endpoints, though the absolute magnitude of improvement was modest. The FSDS-DAO score improved by approximately 0.7 points more than placebo on an 11-point scale. The FSFI desire domain improved by approximately 0.5 points more than placebo on a 6-point scale.
The most common adverse events were nausea (40.0%), flushing (20.3%), injection site reactions (13.2%), and headache (11.3%). The cardiovascular findings from White et al. (2017) informed the FDA's risk mitigation strategy: the label limits dosing frequency (no more than once per 24 hours, no more than 8 doses per month) and excludes patients with uncontrolled hypertension.
A critical detail: the 6 mmHg systolic increase is an average. Individual responses vary, and some patients experienced larger increases. The ambulatory blood pressure monitoring data showed that the peak effect occurred at approximately 2-4 hours post-dose, overlapping with the timeframe of maximum pharmacodynamic effect on sexual function. The simultaneous presence of peak blood pressure increase and peak therapeutic effect means there is no timing strategy that separates the two.
MC4R Obesity: When Blood Pressure Goes the Other Way
The MC4R-blood pressure connection becomes paradoxical in genetic obesity. MC4R loss-of-function mutations cause severe early-onset obesity (MC4R deficiency is the most common monogenic cause of obesity, affecting approximately 5% of severely obese individuals), yet these patients have lower blood pressure than weight-matched controls.
Giannopoulou et al. (2026) reported lessons from a multigenerational MC4R-deficient family, documenting the obesity phenotype across age groups and how it responds (or fails to respond) to conventional interventions.[6]
Bhatnagar et al. (2025) demonstrated that tirzepatide (a dual GLP-1/GIP receptor agonist) produced weight reduction in people with MC4R-deficient obesity, published in Nature Medicine. This is clinically relevant because it shows that GLP-1-based drugs can achieve weight loss through pathways that bypass MC4R entirely, avoiding the blood pressure increase that MC4R agonists would cause.[7]
Hitaka et al. (2026) tested semaglutide, tirzepatide, and retatrutide against MC4R-deficient obesity models, further documenting the efficacy of incretin-based approaches in patients where the melanocortin pathway is non-functional.[8]
Salama et al. (2026) reviewed treatment approaches for obesity in children with heterozygous MC4R variants, a population where partial MC4R function produces intermediate phenotypes in both obesity severity and blood pressure response to melanocortin drugs. Children with one functional and one non-functional MC4R copy have milder obesity than those with complete deficiency, and their cardiovascular response to MC4R agonists is likely intermediate as well, though this has not been systematically studied.[9]
The convergence of MC4R genetics and GLP-1 pharmacology has practical implications: for patients with MC4R-pathway obesity, GLP-1-based treatments offer an alternative that does not carry the inherent blood pressure liability of MC4R agonism. For patients with intact MC4R pathways, the melanocortin system remains a viable target, but blood pressure monitoring must accompany any MC4R agonist therapy.
Engineering Around the Blood Pressure Problem
If MC4R activation inherently raises blood pressure, can melanocortin-based drugs be designed to retain their therapeutic effects (appetite suppression, sexual function) while avoiding the cardiovascular risk?
Ashlaw et al. (2026) developed a dual MC4R/GLP-1R multiple agonist for treating diabetes and obesity. The rationale: combining melanocortin-mediated appetite suppression with GLP-1-mediated metabolic effects might allow lower MC4R engagement (and thus smaller blood pressure effects) while maintaining or improving weight loss efficacy. In preclinical models, the dual agonist produced sustained weight loss. GLP-1-based treatments have significant side effects associated with high discontinuation rates, and this combination approach aims to improve tolerability while maintaining efficacy.[10]
Dahir et al. (2024) found that subthreshold activation of the melanocortin system caused generalized sensitization to multiple anorectic (appetite-suppressing) agents simultaneously. In other words, a dose of MC3R/MC4R agonist too low to suppress appetite on its own made the brain more responsive to other satiety signals. This has direct implications for blood pressure: if subthreshold melanocortin doses can enhance the efficacy of other appetite suppressants, patients might achieve adequate weight loss with MC4R engagement levels too low to meaningfully raise blood pressure.[11]
Ozbay et al. (2026) explored nasal application of peptides targeting MC4R and ghrelin receptors to modulate food intake. Intranasal delivery targets the hypothalamus more directly than systemic injection, potentially achieving central MC4R activation at lower systemic drug exposure. Whether this reduces peripheral cardiovascular effects remains to be tested.[12]
Ericson et al. (2024) incorporated extracyclic arginine residues into a melanocortin macrocyclic agonist, exploring how structural modifications alter receptor subtype selectivity. The specific positioning and number of arginine residues influenced which melanocortin receptor subtypes the peptide activated, demonstrating that rational peptide design can shift selectivity profiles. Engineering peptides that activate MC4R's appetite circuits while sparing its cardiovascular circuits is theoretically possible if the downstream signaling pathways diverge, but no such biased agonist has been demonstrated for MC4R. The concept of biased agonism, where a ligand selectively activates one signaling pathway downstream of a receptor while not activating another, is well-established for other GPCRs but remains unproven for melanocortin receptors.[13]
What This Means for Melanocortin Peptide Users
The blood pressure effect of MC4R agonists is real, reproducible, and mechanism-based. It is not idiosyncratic (affecting only some individuals) or dose-independent. Every person who activates MC4R will experience some degree of sympathetic nervous system activation and blood pressure increase.
For bremelanotide users, the transient nature (resolving within 8-10 hours) and modest magnitude (6 mmHg systolic on average) make the risk manageable in people with normal baseline blood pressure. The FDA's contraindication for uncontrolled hypertension reflects the additive risk: a 6 mmHg increase on top of a systolic baseline of 160 mmHg pushes further into dangerous territory.
For Melanotan II users, the risk is less defined because doses are uncontrolled, purity is variable, and cardiovascular monitoring is absent. The same pharmacology applies, but the safety guardrails present in the bremelanotide clinical program do not exist in the gray market.
For setmelanotide users with genetic obesity, the chronic blood pressure effect must be balanced against the substantial weight loss benefit. Cardiovascular monitoring per the FDA label is not optional; it is the minimum safety requirement for sustained MC4R agonism.
For the obesity drug development field, the MC4R blood pressure effect is a design constraint that shapes the next generation of melanocortin-based therapeutics. Dual agonists, subthreshold dosing strategies, MC3R-selective approaches, and biased agonists all represent attempts to capture the metabolic benefits of melanocortin signaling while minimizing its cardiovascular cost. The ideal melanocortin-based obesity drug would suppress appetite, promote satiety, and enhance energy expenditure without increasing sympathetic tone to the heart and vasculature. No molecule has achieved this separation in humans, but the strategies described above suggest it may be pharmacologically possible.
Chawathe et al. (2026) investigated the stability profile of a therapeutic alpha-MSH analog, examining how storage conditions and formulation affect the peptide's integrity. Stability matters for cardiovascular safety because degradation products of melanocortin peptides may have altered receptor selectivity, potentially shifting the MC4R/MC3R activation ratio and producing unpredictable blood pressure effects.[14]
The Bottom Line
Melanocortin peptides that activate MC4R raise blood pressure through direct stimulation of the sympathetic nervous system. This is documented in bremelanotide clinical trials (6 mmHg systolic increase), confirmed by human genetics (lower hypertension prevalence in MC4R-deficient individuals), and represents a fundamental pharmacological property of MC4R agonism rather than an avoidable side effect. Current drug development strategies aim to separate the metabolic and sexual function benefits of melanocortin signaling from its cardiovascular effects through combination approaches, subthreshold dosing, and receptor-selective design.